ClinicalTrials.gg
Not yet recruitingNCT06563752Updated Aug 21, 2024

Exploring the Effectiveness of Digital Anti-stigma Therapy on Illness Perception and Perceived Stigma in Patients With Schizophrenia and Their Primary Caregivers

An interventional study of Participants will use 3D glasses to view VR educational information and routine care in Schizophrenia, sponsored by National Yang Ming Chiao Tung University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by National Yang Ming Chiao Tung University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Schizophrenia with a site in Taiwan — 23 open to participants now, 26 under way, none of them phase 3. Schizophrenia · Taiwan.

Planned enrollment
33rd of 153
360 · median 85
Started
2024
with 7 others
No phase
56 of 181
9 open now
Primary completion
2026-12
later than 9 of 25 live
Registered
166th of 181
by date
Lead sponsor
7 of 181
National Yang Ming Chiao Tung University

Among the 181 studies in Schizophrenia with a site in Taiwan, this one is the 33rd largest by planned enrollment of the 153 interventional ones that give a count, is one of 8 that started in 2024, is one of 56 with no phase, reaches primary completion later than 9 of the 25 other live ones, and was the 166th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

23 of the 181 studies in Schizophrenia with a site in Taiwan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Schizophrenia with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to investigate the relationship between illness insight, self-stigma in patients with schizophrenia, and the awareness and associated stigma experienced by their families, as well as the predictors of these factors. The study will use information technology strategies for educational purposes, specifically employing 3D glasses for delivering this education. The goal is to develop a disease adaptation program that involves both patients and their families, helping to enhance disease awareness and improve stigma experiences.

Read the detailed description
  • Background:** Research has confirmed that family members of patients with schizophrenia often lack awareness of the illness and are affected by stigma, leading them to be reluctant to seek help. This reluctance impacts patients' medication adherence, increases the severity of the illness, and results in recurrent episodes and deteriorating social functioning. In Chinese societies, where maintaining face is important, the caregiving burden on families and associated stigma are even more pronounced. In Taiwan, there is a lack of interventions using virtual reality for family members.
  • Objective:** To evaluate the effectiveness of a digital anti-stigma therapy in improving illness awareness and reducing associated stigma among patients with schizophrenia and their family members.
  • Methods:** This pioneering study employs a randomized controlled trial design, involving 180 patients with schizophrenia and their family members from psychiatric medical institutions in northern Taiwan. Participants are randomly assigned to two groups: one receiving standard care and the other receiving standard care plus VR video intervention. Research tools include questionnaires on illness awareness (family and patient versions), internalized stigma scales, and family-associated internalized stigma scales. Data collection occurs at baseline, immediately post-intervention, and three months later. The t-test and χ2 test are used to assess group homogeneity, and generalized estimating equations are applied to explore the effectiveness of the intervention after controlling for basic attributes.
  • Expected Results/Clinical Application:** The experimental group is anticipated to show significantly greater improvement in outcome measures compared to the control group. Implementing this intervention clinically could enhance family members' awareness of the illness and improve their experience of stigma, thereby supporting patients in adapting to their illness and stabilizing their community living.
03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient group

  1. Age ≥ 18 years;
  2. Patients who meet the criteria for schizophrenia or the ICD-10 diagnosis code F20, including those who are expected to be discharged from a psychiatric ward within two weeks or are outpatients;
  3. Have family members involved in caregiving (i.e., relatives who assist with daily needs, supervise medication, help with medical visits, and maintain contact with hospital staff during hospitalization, including non-blood-related cohabitants);
  4. Are literate, able to independently read and complete questionnaires, can operate basic tablet or smartphone functions after instruction, and are willing to participate in this study.

Family group

  1. Age ≥ 18 years;
  2. Family members providing care for psychiatric outpatients or inpatients diagnosed with schizophrenia (i.e., relatives who assist with daily needs, supervise medication, help with medical visits, and maintain contact with hospital staff during hospitalization, including non-blood-related cohabitants);
  3. Literate, able to independently read and complete questionnaires, can operate basic tablet or smartphone functions after instruction, and are willing to participate.

Exclusion criteria

Exclusion Criteria:

Patient group

(1) Patients with co-occurring personality disorders, substance or alcohol addiction, or organic brain damage; (2) Individuals living alone without close family contact; (3) Patients who will reside in a rehabilitation facility after discharge. Family group

  1. Individuals with mental disorders, who are illiterate, or unable to independently read and complete questionnaires.
  2. Family members who cannot use smartphones or do not have access to smart technology.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
360 participants (estimated)

Study arms

  • Placebo comparator
    Routine care

    Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.

    Other: routine care

  • Experimental
    Experimental

    The experimental group, referred to as the Dyad, involved both the caregiver and the patient wearing 3D glasses to watch educational VR content. The VR content included the following topics: 1. Understanding psychiatric symptoms, including symptoms, disease course, treatment, and prognosis. 2. Knowledge of medications and their relationship to symptom stability, as well as how to manage side effects. 3. Schizophrenia as a chronic illness, drawing comparisons to other chronic diseases. 4. Signs of disease relapse. 5. How to manage persistent psychotic symptoms of schizophrenia, such as delusions, hallucinations, paranoia, and negative symptoms. 6. How to interact and communicate with the patient. 7. Coping with stress, stress management, and suicide prevention. 8. Available resources.

    Other: Participants will use 3D glasses to view VR educational information

Interventions

  • OtherParticipants will use 3D glasses to view VR educational information

    Participants will use 3D glasses to view VR educational information, which includes: 1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis. 2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects. 3. Schizophrenia as a chronic illness, with analogies to other chronic diseases. 4. Signs of disease relapse. 5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms. 6. Strategies for interacting and communicating with patients. 7. Stress management and adjustment, as well as suicide prevention. 8. Available resources.

  • Otherroutine care

    Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.

06

What researchers measure

Primary outcomes

  1. Positive and Negative Syndrome Scale

    This scale primarily assesses the severity of psychiatric disorders and was originally developed by Kay et al. (1987). It includes three dimensions: positive symptoms, negative symptoms, and general psychopathology, with a total of 30 items.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  2. The Schedule for the Assessment of Insight

    This is a semi-structured interview questionnaire developed by David (1990), primarily used to assess illness insight and perceptions of the illness in psychiatric disorders. It includes three aspects: illness awareness, the importance of treatment, and disease recognition, with a total of 7 items.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  3. Internalized Stigma of Mental Illness

    This scale primarily measures the subjective self-stigma experienced by individuals with mental illness and was developed in collaboration with patients. It includes 29 items across five dimensions: alienation, stereotype endorsement, perceived discrimination, social withdrawal, and anti-stigma coping ability.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  4. Medication Adherence Rating Scale

    This self-report scale assesses patients' medication attitudes and adherence behaviors over the past week. It consists of 10 true/false questions, with scores ranging from 1 to 7 indicating poor adherence and 8 to 10 indicating good adherence.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  5. Drug Attitude Inventory-10

    This is a self-report scale primarily used to assess patients' attitudes towards medication.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  6. Illness Perception Questionnaire-Revised Version for Families of Patients with Schizophrenia

    This is a survey questionnaire designed to assess illness awareness among the family members of individuals with schizophrenia. It includes 38 items across 7 dimensions, evaluating participants' knowledge about schizophrenia and its management, causes, prevalence, prognosis, and treatment.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  7. Affiliate Stigma Scale

    The primary purpose is to assess the caregiver's perception of internalized stigma. The scale consists of 22 items, covering three aspects: cognition, emotion, and behavior.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  8. Caregiver Burden Scale

    The main purpose is to assess the burden level of caregivers of psychiatric patients. The scale contains 18 questions, measuring the actual problems and feelings that arise from caregiving. The scale includes five subdimensions.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  9. World Health Organisation- Five Well-Being Index

    To assess the perception of Well-Being over the past two weeks.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

  10. Multidimensional Scale of Perceived Social Support

    To assess social support from different sources. The scale consists of 12 items across three dimensions: family, friends, and significant others.

    Time frame: The assessment will be conducted three times: before the intervention, immediately after the intervention, and three months after the intervention.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Dec 2026, 26 months later.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 26 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartEst.
Oct 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06563752
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Oct 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 21, 2024

Study contacts

Chiu-Yueh Yang, PhD
Contact
Cyyang530904@nycu.edu.tw
+8860228267388
Jia-Min Li, MSN
Contact
louislee0720@gmail.com
+886972988076

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion